Acumen pharmaceuticals to participate in the h.c. wainwright 2nd annual bioconnect investor conference

Charlottesville, va., may 13, 2024 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of alzheimer's disease, announced today that management will participate in a fireside chat at the h.c. wainwright 2nd annual bioconnect conference on monday, may 20, 2024, at 12:30 p.m. et.
ABOS Ratings Summary
ABOS Quant Ranking